Ekso Bionics Files 8-K on Operations and Financials

TL;DR

EKSO filed an 8-K on Jan 13, 2025, detailing financial results and operations.

AI Summary

Ekso Bionics Holdings, Inc. filed an 8-K on January 13, 2025, reporting on results of operations, financial condition, and other events. The filing includes financial statements and exhibits, with the company's principal executive offices located at 101 Glacier Point, Suite A, San Rafael, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Ekso Bionics' financial performance and operational status, impacting their investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing providing standard corporate information and financial updates, not indicating any immediate or significant risk.

Key Players & Entities

• Ekso Bionics Holdings, Inc. (company) — Registrant
• 101 Glacier Point, Suite A, San Rafael, California 94901 (location) — Principal Executive Offices
• January 13, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capi
• $5.0 million — 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected to b
• $5.1 m — d to be in the range of $5.0 million to $5.1 million, which is expected to be a Compan
• $4.8 million — ny record, compared to total revenue of $4.8 million for the fourth quarter of 2023. Estima
• $6.5 m — imated cash as of December 31, 2024 was $6.5 million, compared to cash of $8.6 million
• $8.6 million — 4 was $6.5 million, compared to cash of $8.6 million as of December 31, 2023. For the fourt
• $1.5 million — of 2024, the Company used an estimated $1.5 million of net cash in operations, compared to
• $1.6 million — of net cash in operations, compared to $1.6 million for the same period in 2023. The estim

Filing Documents

• ekso20250108_8k.htm (8-K) — 35KB
• ex_763239.htm (EX-99.1) — 12KB
• logo.jpg (GRAPHIC) — 4KB
• 0001437749-25-000928.txt ( ) — 187KB
• ekso-20250113.xsd (EX-101.SCH) — 3KB
• ekso-20250113_def.xml (EX-101.DEF) — 11KB
• ekso-20250113_lab.xml (EX-101.LAB) — 15KB
• ekso-20250113_pre.xml (EX-101.PRE) — 11KB
• ekso20250108_8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 13, 2025, Ekso Bionics Holdings, Inc. (the "Company") issued a press release (the "Press Release") announcing certain preliminary financial results for the fourth quarter 2024. The full text of the Press Release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, and such information shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Other Events

Item 8.01 Other Events In the Press Release, the Company reports the following preliminary financial results: Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million to $5.1 million, which is expected to be a Company record, compared to total revenue of $4.8 million for the fourth quarter of 2023. Estimated cash as of December 31, 2024 was $6.5 million, compared to cash of $8.6 million as of December 31, 2023. For the fourth quarter of 2024, the Company used an estimated $1.5 million of net cash in operations, compared to $1.6 million for the same period in 2023. The estimated, projected or anticipated financial results, financial condition or other financial information discussed in this Current Report on Form 8-K are based on management's preliminary unaudited analysis of financial results for the quarter ended December 31, 2024. As of the date of this Current Report on Form 8-K, the Company has not completed its financial statement reporting process for the quarter ended December 31, 2024, and the Company's independent registered accounting firm has not audited the preliminary financial data discussed in this Current Report on Form 8-K. During the course of the Company's quarter-end closing procedures and review process, including the finalization of its financial statements for and as of the quarter ended December 31, 2024, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary results.

Forward-Looking Statements

Forward-Looking Statements Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the estimated financial results. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company's finalization of its financial statements for and as of the quarter ended December 31, 2024, information or new changes in facts or circumstances that may occur prior to the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2024 that are required to be included in such annual report and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statements made in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K. The Company does not undertake to update these forward-looking statements, except as required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description 99.1 Press Release, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EKSO BIONICS HOLDINGS, INC. By: /s/ Jerome Wong Name: Jerome Wong Title: Chief Financial Officer Dated: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR